Vaxcyte (PCVX) Preferred Stock Liabilities (2019 - 2020)
Vaxcyte's (PCVX) quarterly Preferred Stock Liabilities came in at $55.2 million in Q1 2020, up 46.32% year-on-year from $37.7 million in Q2 2019, and down 65.6% on a QoQ basis from $160.3 million in Q4 2019.
Vaxcyte (PCVX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Vaxcyte (PCVX) has 2 years of Preferred Stock Liabilities data on file, last reported at $55.2 million in Q1 2020.
- On a quarterly basis, Preferred Stock Liabilities rose 46.32% year-over-year to $55.2 million in Q1 2020; TTM through Mar 2020 was $55.2 million, a 46.32% increase from a year earlier, with the FY2019 full-year figure at $160.3 million, up 190.67% from the prior year.
- Preferred Stock Liabilities for Q1 2020 stood at $55.2 million, down from $160.3 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for PCVX reached as high as $160.3 million in Q4 2019 and fell as low as $25.0 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Vaxcyte | 7.64 Bn | 7.64 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 55.15 Mn |
| Dec 31, 2019 | 160.31 Mn |
| Sep 30, 2019 | 24.97 Mn |
| Jun 30, 2019 | 24.97 Mn |
| Mar 31, 2019 | 37.69 Mn |